secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001372514-24-000117
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa
--------------------------------------------------------------------------------

- ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.
- Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.
- First patient dosing expected next year after validation of novel functional vision endpoints.
- KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.
- Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/0001372514-24-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000117/kprx-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer